Core Insights - MiMedx Group, Inc. (NASDAQ:MDXG) has reported record quarterly and full-year revenue and profitability, driven by strong performance in its wound care and surgical segments, both achieving double-digit growth [1] Financial Performance - In Q4, the company achieved a revenue of $118.1 million, reflecting a year-over-year growth of 27.11%, exceeding market expectations by $11.32 million [2] - The earnings per share (EPS) for Q4 was $0.10, surpassing expectations by $0.01 [2] - The wound care segment grew by 28% year-over-year, while the surgical segment revenue increased by 25% [2] - Gross profit margins improved by 200 basis points to 86% for Q4, attributed to a better product mix compared to the previous year [2] Future Outlook - For fiscal 2026, the company anticipates revenue in the range of $340 million to $360 million, with an adjusted EBITDA margin expected to be in the mid to high teens [3] - MiMedx Group specializes in developing and distributing advanced placental tissue allografts for wound care, surgical, and burn applications, utilizing proprietary processing methods to assist clinicians in treating chronic and hard-to-heal wounds [3]

Core Viewpoint - MiMedx Group, Inc. (NASDAQ:MDXG) is recognized as one of the best biotech stocks under $20, despite recent adjustments to price targets by analysts due to changes in CMS guidance affecting wound care volumes [1][2][3]. Group 1: Analyst Adjustments - Craig-Hallum analyst Chase Knickerbocker lowered the price target on MDXG to $10 from $13 while maintaining a Buy rating, citing expected provider confusion and pressure on wound care volumes in Q1 2026 [2]. - Northland Securities also reduced its price target on MDXG to $10 from $12, maintaining an Outperform rating, and adjusted FY2026 and FY2027 forecasts due to near-term uncertainties related to CMS's flat-rate coverage for skin substitutes [3]. Group 2: Company Overview - MiMedx Group, Inc. is a U.S. biomedical company that specializes in developing and distributing advanced placental tissue allografts for applications in wound care, surgery, and burns, utilizing proprietary processing methods to aid in treating chronic and hard-to-heal wounds [4].